Sun Pharma Advanced Research (NSE:SPARC, BOM:532872) narrowed its consolidated loss to 597.7 million Indian rupees in the fiscal fourth quarter ended March 31 from 1.06 billion rupees a year ago.
Loss per share fell to 1.84 rupees from 3.26 rupees, according to a Monday filing to the Indian stock exchanges by the biopharmaceutical company.
Revenue from operations in fiscal Q4 increased to 271.9 million rupees from 165.6 million rupees a year earlier.
The company's shares were down nearly 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.